media – Page 642 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

FDA Grants Priority Review To Gilotrif For Uncommon EGFR Mutations In Advanced NSCLC

Boehringer Ingelheim announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 (L861Q), G719X or S768I substitution mutations as detected by an FDA-approved test.
- Source: careers.biospace
- 555
- October 13, 2017
EGFR New Approvals NSCLC sNDA
19th Asia Pacific Rheumatology APLAR Congress

The19th Asia Pacific League of Associations for Rheumatology Congress - APLAR 2017 which will be hosted in Dubai UAE from October 16-20, 2017 at the Dubai World Trade Center.
- Source: medical-events
- 790
- October 13, 2017
Exhibitions & Activities Rheumatology
Iraq Medicare Exhibition & Conference

Medicare Iraq - Erbil, the 10th International Healthcare Exhibition & Conference is the premier event serving Iraq's healthcare sector. Medicare Iraq Erbil 2017 will be held on 15-18 October 2017 at Erbil International Fair Ground, Erbil, Iraq.
- Source: medical-events
- 672
- October 13, 2017
Exhibitions & Activities Iraq Medicare
SDEF’s 13th Annual Women’s & Pediatric Dermatology Seminar

SDEF's 13th Annual Women's & Pediatric Dermatology Seminar will be held from 13 Oct to 14 Oct.
- Source: medical-events
- 778
- October 13, 2017
Dermatology Exhibitions & Activities
ICR researchers demonstrate use of genetic test for prostate cancer therapy

Scientists from the Cancer Biomarkers laboratory team of the Institute of Cancer Research in the UK have carried out research to demonstrate the use of a quick genetic test for the targeted treatment of prostate cancer.
- Source: medicaldevice-network
- 651
- October 12, 2017
cancer genetic prostate Researches
Pfizer unloads Colorado plant as it continues to hive off unwanted Hospira operations

Pfizer has sold another Hospira plant, its second in eight weeks, as it continues to whittle down the unwanted operations it picked up in its $15 billion buyout of the sterile drug manufacturer.
- Source: Fiercepharm
- 517
- October 12, 2017
API Company Insight Hospira
FDA approves LivaNova’s VNS therapy system for epilepsy

UK-based firm LivaNova has obtained approval from the US Food and Drug Administration (FDA) for its new Vagus Nerve Stimulation (VNS) Therapy System designed to treat drug-resistant epilepsy.
- Source: medicaldevice-network
- 832
- October 12, 2017
Company Insight epilepsy New Approvals VNS
Merck buys into KalVista and its DME candidate

Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million. Under the deal, Merck, which is known as MSD outside of the US and Canada, is paying KalVista $37 million upfront and taking a 9.9 percent stake in the firm in return for access to its experimental diabetic macular oedema drug KVD001.
- Source: Pharmatime
- 600
- October 12, 2017
diabetic macular Market Views oedema
FDA grants orphan drug status to UniQure’s Huntington’s Disease treatment

Dutch biotech UniQure has won orphan drug designation (ODD) for its investigational treatment for Huntington’s Disease, a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioural abnormalities and cognitive decline.
- Source: 4-traders
- 762
- October 12, 2017
Huntington’s Disease neurodegenerative New Approvals ODD
Ebola vaccine tests hailed a success

The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
- Source: medicalxpress
- 1,181
- October 11, 2017
Ebola Market Views vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.